INTRODUCTION AND INDICATIONS FOR TREATMENT
Aplastic anaemia (AA) occurs in all age groups, but within two peaks from 10 to 20 years and 460 years. Because AA is a rare disease, it is of particular importance to exclude hypocellular myelodysplastic syndrome (MDS), because MDS is a relatively common BM disorder of the elderly population, and it can often be difficult to distinguish between these two conditions. 1 Hence the need for careful review of the blood film and BM aspirate examination, along with trephine and cytogenetics, as discussed in a previous article in this journal. Older age per se is not a reason for withholding specific treatment in elderly patients with AA who are 460 years old, even 480 years old. There is no place for allogeneic haematopoietic SCT as first-line treatment in patients 460 years of age. Immunosuppressive treatment is a reasonable option: response to immunosuppression in AA is independent of age, but treatment is associated with increased mortality in older patients. Therefore, the treatment decision in the older patients and the type of immunosuppressive treatment used should be based on several factors, including (i) severity of the disease, especially severity of neutropenia, and its clinical complication of infection, (ii) the presence of comorbidities and (iii) the willingness of the patients and their family members to be treated with specific therapy other than supportive care.
IMMUNOSUPPRESSIVE THERAPY
For patients eligible for immunosuppressive treatment, the choice of first-line immunosuppression should be based on the risk of severe infections, and the requirement for a rapid response vs slower stabilisation of their condition, as well as disease severity. Ideally the least toxic and the most convenient treatment should be used. The aim is to treat patients with severe disease, and/or those requiring rapid response because of the imminent risk of a lethal complication, more intensely than those with less severe disease or with a condition allowing more time until response is achieved. The combination of antithymocyte globulin (ATG) and cyclosporine (CsA), which is the gold standard in younger patients, results in faster and more complete response in AA than CsA alone. However, ATG treatment needs hospitalisation and is associated with acute and delayed toxicity, particularly in elderly patients. As the main cause of death of patients 460 years is infection, 2 patients at high risk of infections may be considered for the combination of ATG and CsA. CsA should be used with caution in elderly patients, as they are at more risk of nephrotoxicity and hypertension. Regular CsA blood level monitoring must be performed. In contrast, anaemia and thrombocytopenia are usually not reasons for upfront intensive treatment, as platelet and red cell transfusions are usually safe and efficient. An exception would be patients who are heavily sensitised and refractory to random donor-platelet transfusions, unless a good supply of HLA-matched platelets is available. Worsening of thrombocytopenia occurs during ATG administration and at the period of serum sickness, hence the need for adequate platelet support. Before treatment with ATG, elderly patients must be carefully assessed medically, as they show an inferior survival after ATG compared to younger patients 2,3 and are at more risk of infection, bleeding, heart failure and cardiac arrhythmias.
In non-severe AA, it has been shown that the combination of ATG with CsA is significantly better than CsA alone with respect to response rate and disease-free survival. Patients treated with CsA alone more often need to be retreated with a second course of immunosuppression using ATG and CsA. However, there is no difference in OS because CsA-refractory patients may respond to second-line treatment with ATG and CsA. 4 This means that those patients who respond to first-line CsA will benefit, as they can be treated as outpatients and without being exposed to the additional toxicity of ATG; in addition, non-responders, if they do not present with life-threatening infection, may still respond to more intensive immunosuppression.
( Figure 1 ). However, they need to be carefully assessed medically beforehand to determine whether they are fit enough to receive ATG or not. The use of CsA alone is an alternative option but is associated with delayed response and reduced-response rate compared with the combination of ATG and CsA. In these highrisk patients, delay in response by using a less efficient immunosuppression (CsA alone) may result in increased risk of serious infection. The benefit from a faster and more complete response to treatment may exceed the risk of the toxicity of the more intense immunosuppression, but this should always be evaluated on an individual patient basis.
THE ELDERLY PATIENT IN THE OUTPATIENT SETTING
For patients who are not at immediate risk of severe infections, and who are therefore managed as outpatients and receive supportive care until response, first-line treatment with CsA alone is recommended (Figure 1 ). This definition mainly includes patients with non-severe AA, and particularly with a neutrophil count 40.5 Â 10 9 /L without infection. Severe thrombocytopenia alone is not usually an indication for hospitalisation. Severe AA with mainly severe thrombocytopenia and anaemia, but without severe neutropenia, can be included into this group. The use of androgens, particularly in men, can be considered in patients intolerant to CsA, for example, those with renal impairment. However, androgens are associated with hepatotoxicity, congestive cardiac failure, prostatic enlargement, elevated blood lipids, mood changes and other side effects, and require careful monitoring of the patient.
THOSE ELDERLY PATIENTS REFUSING OR UNABLE TO RECEIVE TREATMENT
Such patients should receive best supportive care alone. The outcome of these patients should be recorded as well.
TRANSPLANTATION IN THE ELDERLY PATIENTS
There are virtually no data on patients aged 460 years with allogeneic haematopoietic SCT as first-line treatment, although there are some data in patients 460 years receiving haematopoietic SCT after having failed optimal immunosuppression. This does not apply to patients with a syngeneic donor in whom transplantation should be the first-line therapy (Figure 1) . Haematopoietic SCT is an option in elderly patients refractory to immunosuppression using, for example, a reduced-intensity conditioning regimen with fludarabine, low-dose CY and ATG or alemtuzumab. 5, 6 Even though it is impossible to extrapolate across different disease entities, it is of interest that in an EBMT (European Group for Blood and Marrow Transplantation) study of patients with MDS transplanted using reduced-intensity conditioning haematopoietic SCT, there was no significant difference in nonrelapse mortality for patients aged 460 years compared with those aged 50-60 years, 7 and an CIBMTR (Center for International Blood and Marrow Transplant Research) study in MDS showed that older age has no impact on OS, disease-free survival as well as nonrelapse mortality. 8 
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